Idexx Labs (IDXX) Shareholder Bluecrest Capital Management LTD Trimmed Stake as Market Value Rose; Realpage (RP) Shareholder Summit Creek Advisors Boosted Holding

May 24, 2018 - By Dolores Ford

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Logo

Bluecrest Capital Management Ltd decreased its stake in Idexx Labs Inc (IDXX) by 47.51% based on its latest 2017Q4 regulatory filing with the SEC. Bluecrest Capital Management Ltd sold 6,312 shares as the company’s stock rose 21.09% while stock markets declined. The institutional investor held 6,975 shares of the health care company at the end of 2017Q4, valued at $1.09 million, down from 13,287 at the end of the previous reported quarter. Bluecrest Capital Management Ltd who had been investing in Idexx Labs Inc for a number of months, seems to be less bullish one the $17.73B market cap company. The stock increased 2.09% or $4.17 during the last trading session, reaching $204.16. About 422,628 shares traded. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 23.99% since May 24, 2017 and is uptrending. It has outperformed by 12.44% the S&P500.

Summit Creek Advisors Llc increased its stake in Realpage Inc (RP) by 21.35% based on its latest 2017Q4 regulatory filing with the SEC. Summit Creek Advisors Llc bought 57,250 shares as the company’s stock rose 18.81% while stock markets declined. The institutional investor held 325,457 shares of the technology company at the end of 2017Q4, valued at $14.42M, up from 268,207 at the end of the previous reported quarter. Summit Creek Advisors Llc who had been investing in Realpage Inc for a number of months, seems to be bullish on the $4.98B market cap company. The stock increased 0.34% or $0.2 during the last trading session, reaching $58.5. About 746,437 shares traded or 47.71% up from the average. RealPage, Inc. (NASDAQ:RP) has risen 49.71% since May 24, 2017 and is uptrending. It has outperformed by 38.16% the S&P500.

Investors sentiment decreased to 0.81 in 2017 Q4. Its down 0.05, from 0.86 in 2017Q3. It fall, as 30 investors sold IDXX shares while 217 reduced holdings. 64 funds opened positions while 137 raised stakes. 72.13 million shares or 17.89% less from 87.85 million shares in 2017Q3 were reported. Zacks Mgmt holds 7,053 shares. Farmers & Merchants Investments Inc stated it has 232 shares or 0% of all its holdings. State Board Of Administration Of Florida Retirement Systems invested in 0.05% or 129,491 shares. Trust Of Vermont stated it has 423 shares. Susquehanna International Group Limited Liability Partnership invested 0% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Amundi Pioneer Asset Incorporated reported 0.01% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Advisory Net Ltd Company reported 0.01% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Hbk Limited Partnership reported 0.02% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Connors Investor owns 0.03% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 1,350 shares. Evercore Wealth Limited Liability Co, New York-based fund reported 59,974 shares. Gateway Inv Advisers Ltd Liability Com invested 0.01% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX). 1832 Asset Limited Partnership holds 0% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 160 shares. Apg Asset Management Nv has 0.03% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 127,300 shares. Moreover, Putnam Fl Invest Mngmt Communications has 0.07% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 4,849 shares. Cahill Fincl Advsrs holds 0.1% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 1,300 shares.

Among 11 analysts covering IDEXX Laboratories (NASDAQ:IDXX), 7 have Buy rating, 2 Sell and 2 Hold. Therefore 64% are positive. IDEXX Laboratories had 29 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) earned “Buy” rating by C.L. King on Friday, July 28. The rating was upgraded by Bank of America to “Buy” on Wednesday, August 23. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, October 5. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, October 29 report. Raymond James downgraded IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Friday, August 28 to “Market Perform” rating. On Friday, February 2 the stock rating was maintained by Bank of America with “Buy”. Feltl & Co upgraded IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Friday, July 24 to “Hold” rating. On Friday, February 3 the stock rating was downgraded by Feltl & Co to “Sell”. Bank of America reinitiated the shares of IDXX in report on Thursday, September 29 with “Neutral” rating. The rating was initiated by Credit Suisse on Thursday, February 4 with “Outperform”.

Since January 9, 2018, it had 2 buys, and 7 insider sales for $23.44 million activity. The insider AYERS JONATHAN W sold 22,000 shares worth $3.91M. Kingsley Lawrence D had bought 1,000 shares worth $178,045. $179,580 worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) shares were bought by Claflin Bruce L.. JUNIUS DANIEL M sold $565,232 worth of stock or 2,974 shares. MCKEON BRIAN P sold $1.20 million worth of stock.

Analysts await IDEXX Laboratories, Inc. (NASDAQ:IDXX) to report earnings on August, 7. They expect $1.18 earnings per share, up 24.21% or $0.23 from last year’s $0.95 per share. IDXX’s profit will be $102.50 million for 43.25 P/E if the $1.18 EPS becomes a reality. After $1.01 actual earnings per share reported by IDEXX Laboratories, Inc. for the previous quarter, Wall Street now forecasts 16.83% EPS growth.

More recent IDEXX Laboratories, Inc. (NASDAQ:IDXX) news were published by: Seekingalpha.com which released: “Buy Diamondback Energy On Declines – Cramer’s Lightning Round (5/11/18)” on May 14, 2018. Also Seekingalpha.com published the news titled: “IDEXX: This Medical Equipment Stock Is Overvalued And Could Go Down As Much As 20%” on May 19, 2018. Nasdaq.com‘s news article titled: “IDEXX Laboratories Barks Out Another Successful Quarter” with publication date: May 11, 2018 was also an interesting one.

Bluecrest Capital Management Ltd, which manages about $3.68B US Long portfolio, upped its stake in Kraft Heinz Co by 46,841 shares to 51,157 shares, valued at $3.98 million in 2017Q4, according to the filing. It also increased its holding in Tetra Tech Inc New (NASDAQ:TTEK) by 10,629 shares in the quarter, for a total of 20,052 shares, and has risen its stake in Sm Energy Co (NYSE:SM).

Among 7 analysts covering RealPage (NASDAQ:RP), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. RealPage had 22 analyst reports since June 8, 2016 according to SRatingsIntel. The firm has “Hold” rating given on Wednesday, January 17 by RBC Capital Markets. The rating was maintained by KeyBanc Capital Markets with “Overweight” on Friday, May 4. The stock of RealPage, Inc. (NASDAQ:RP) has “Buy” rating given on Wednesday, February 28 by Stephens. The firm earned “Buy” rating on Friday, December 29 by Stephens. The company was maintained on Sunday, July 23 by RBC Capital Markets. The stock has “Buy” rating by KeyBanc Capital Markets on Monday, February 5. The stock of RealPage, Inc. (NASDAQ:RP) earned “Overweight” rating by Morgan Stanley on Friday, May 4. William Blair upgraded the stock to “Outperform” rating in Wednesday, June 8 report. As per Monday, February 27, the company rating was maintained by Benchmark. The firm earned “Hold” rating on Thursday, November 2 by RBC Capital Markets.

More important recent RealPage, Inc. (NASDAQ:RP) news were published by: Streetinsider.com which released: “RealPage (RP) Prices 7M Common Stock Offering at $57/Share” on May 24, 2018, also Streetinsider.com published article titled: “RealPage (RP) Tops Q1 EPS by 3c; Guides Above Views”, Streetinsider.com published: “RealPage (RP) Announces Proposed 6.5M Share Follow-on Public Offering of Common Stock” on May 21, 2018. More interesting news about RealPage, Inc. (NASDAQ:RP) was released by: Seekingalpha.com and their article: “RealPage’s (RP) CEO Steve Winn on Q1 2018 Results – Earnings Call Transcript” with publication date: May 07, 2018.

Summit Creek Advisors Llc, which manages about $971.18 million and $532.50 million US Long portfolio, decreased its stake in Cavium Inc. (NASDAQ:CAVM) by 37,935 shares to 159,915 shares, valued at $13.41 million in 2017Q4, according to the filing. It also reduced its holding in Callidus Software (NASDAQ:CALD) by 107,015 shares in the quarter, leaving it with 302,540 shares, and cut its stake in Costar Group Inc (NASDAQ:CSGP).

RealPage, Inc. (NASDAQ:RP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>